DUBLIN, Ireland and LIBEREC, Czech Republic, November 14 /PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), the Medical Technology Company focused on the Woundcare, Oralcare and Cardiovascular Health markets today announces that Nanopeutics(TM) s.r.o., ("Nanopeutics"), the specialist subsidiary dedicated to the commercialisation of Nanospider(TM) technology for the global woundcare market, has signed an exclusive partnership agreement with a world leader in the professional woundcare market.
The agreement is for an exclusive six month period and is focused on the development of a range of nanofibre based professional wound care technologies and products. Under the agreement, all development work and associated costs will be paid for by the Nanopeutics(tm) partner as well as payment of an associated undisclosed licence fee for the six months exclusivity period.
The successful conclusion to the development work will lead to an exclusive global royalty bearing licence and supply agreement for Nanospider(TM) based technology and specialist products for the professional woundcare and potential related markets.
The agreement does not cover the consumer wound care market.
Alltracel Pharmaceutical's CEO, Tony Richardson, commented:
"This development agreement represents a significant technological breakthrough into the EUR10 billion professional woundcare sector for Alltracel. For the past year we have been working with a number of potential woundcare partners in successfully testing a range of advanced woundcare product concepts. This significant global partnership agreement, signed today by our specialist Nanopeutics(TM) subsidiary has been facilitated by that validation work.
A specific product and technology development effort is now in place both at Nanopeutics(TM) and at the market leading partner, for the development of a range of advanced nanofibre based product applications and technologies and we look forward to further news in this regard in the next six months
Commercialising Nanospider(TM) technology in the global woundcare market via Nanopeutics(TM) remains a priority business development focus for Alltracel, and outside of this significant development for the professional market, Nanopeutics(TM) is now in discussions with a number of other woundcare companies for consumer woundcare and other applications."
Notes to Editors:
Nanopeutics(TM) s.r.o. ("Nanopeutics") (www.nanopeutics.net) is the specialist Alltracel subsidiary formed as part of a joint venture with Elmarco s.r.o. dedicated to the commercialisation of Nanospider(TM) technology for the global professional and consumer woundcare markets.
Nanopeutics, headquartered in Liberec in the Czech Republic and operating internationally, has been licensed and/or assigned the relevant woundcare and Nanospider(TM) intellectual property and patents. Nanospider(TM) is the novel patented process for spinning polymers into nano-scale fibres for a range of industrial, chemical, micro-electronic and bio-medical applications. The Nanospider(TM) technology has been recognised internationally as a major breakthrough in the mass production of nanofibre materials.
Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc ("Alltracel") is a Medical Technology Company focused on the Woundcare, Oralcare and Cardiovascular Health markets.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel was founded in 1996 and listed on London's Alternative Investment Market in July 2001.
Alltracel has a number of patents in the areas of polysaccharide manipulation and PTFE processes and products as well as a significant collaborative R&D programme in place focused on its markets.
In the consumer Woundcare market m-doc(TM) (Micro Dispersed Oxidized Cellulose; (www.m-doc.com)) is the trading name given to Alltracel's patented technology which is proven as an effective and efficient haemostatic (blood-stopping) agent and is currently being marketed as the leading stops bleeding ingredient brand within recognized woundcare, and relevant first-aid brands worldwide. Alltracel's specialist Nanotechnology subsidiary Nanopeutics(TM) is headquartered in Liberec in the Czech Republic and is dedicated to the commercialisation of Nanospider(TM) technology for the global professional and consumer woundcare markets.
Within the Cardiovascular Health market Alltracel (www.alltracelcvh.com) has developed a novel bioactive compound that, following over two years of scientific research including in vitro, pre-clinical and clinical trials, indicates cardiovascular health (CVH) benefits on its own and in combination with existing CVH products.
The end result is a pioneering, value-adding bioactive that can enhance and differentiate current cardiovascular health products and that can add benefit to current non-health benefiting nutritious finished foods.
m-doc(TM) is a trademark of Alltracel Pharmaceuticals PLC.
Nanospider(TM) and Nanopeutics(TM) are trademarks controlled by Nanopeutics s.r.o.
For Further Information Contact: Dublin: Denise Cronin Alltracel: +353-1-235-2162 press@alltracel.com London: Deborah Scott Financial Dynamics: +44-0207-831-3113 New York: Sean Leous Financial Dynamics: +1-212-850-5626
Alltracel Pharmaceuticals Plc.CONTACT: For Further Information Contact: Dublin: Denise Cronin,Alltracel: +353-1-235-2162, press@alltracel.com. Liberec: Pavel Novotny,Nanopeutics: press@nanopeutics.net. London: Deborah Scott, FinancialDynamics: +44-207-831-3113, New York: Sean Leous, Financial Dynamics:+1-212-850-5626
